Interventional nanotheranostics in hepatocellular carcinoma
暂无分享,去创建一个
[1] Vivek P. Chavda,et al. Biodegradable and removable implants for controlled drug delivery and release application , 2022, Expert opinion on drug delivery.
[2] R. Verma,et al. Fullerenes for the treatment of cancer: an emerging tool , 2022, Environmental Science and Pollution Research.
[3] Vivek P. Chavda,et al. Lyotropic liquid crystals for parenteral drug delivery. , 2022, Journal of controlled release : official journal of the Controlled Release Society.
[4] C. Cristea,et al. Nanotechnology in the Diagnostic and Therapy of Hepatocellular Carcinoma , 2022, Materials.
[5] D. Janas,et al. Application of carbon nanotubes in sensing/monitoring of pancreas and liver cancer. , 2022, Chemosphere.
[6] W. Alshaer,et al. Liposomes: structure, composition, types, and clinical applications , 2022, Heliyon.
[7] Vivek P. Chavda,et al. Phytochemical-loaded liposomes for anticancer therapy: an updated review. , 2022, Nanomedicine.
[8] Xiao-Yi Chen,et al. Metal nanoparticles as a promising technology in targeted cancer treatment , 2022, Drug delivery.
[9] Vivek P. Chavda,et al. Phytochemical Delivery Through Transferosome (Phytosome): An Advanced Transdermal Drug Delivery for Complementary Medicines , 2022, Frontiers in Pharmacology.
[10] W. Wang,et al. Versatile carbon nanoplatforms for cancer treatment and diagnosis: strategies, applications and future perspectives , 2022, Theranostics.
[11] Ruihang Zhang,et al. Advances in Nanoliposomes for the Diagnosis and Treatment of Liver Cancer , 2022, International journal of nanomedicine.
[12] Juan Li,et al. Graphene-based nanomaterials for cancer therapy and anti-infections , 2022, Bioactive Materials.
[13] G. Soraya,et al. Nanotheranostics: A powerful next-generation solution to tackle hepatocellular carcinoma , 2022, World journal of gastroenterology.
[14] M. Bhat,et al. Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment , 2021, Pharmaceutics.
[15] S. Gan,et al. New challenges in the use of nanomedicine in cancer therapy , 2021, Bioengineered.
[16] C. Allen,et al. Turning down the heat: The case for mild hyperthermia and thermosensitive liposomes. , 2021, Nanomedicine : nanotechnology, biology, and medicine.
[17] A. Zamyatnin,et al. Nanomedicine for increasing the oral bioavailability of cancer treatments , 2021, Journal of Nanobiotechnology.
[18] Lei Cao,et al. Engineering nanotheranostic strategies for liver cancer , 2021, World journal of gastrointestinal oncology.
[19] Vivek P. Chavda,et al. Role of Data Mining in Bioinformatics , 2021, Computation in Bioinformatics.
[20] Vivek P. Chavda,et al. New Bioinformatics Platform‐Based Approach for Drug Design , 2021, Computation in Bioinformatics.
[21] Vivek P. Chavda,et al. In Silico Protein Design and Virtual Screening , 2021, Computation in Bioinformatics.
[22] Vivek P. Chavda,et al. Advanced Computational Methodologies Used in the Discovery of New Natural Anticancer Compounds , 2021, Frontiers in Pharmacology.
[23] T. Karpiński,et al. Nanoparticles for Cancer Therapy: Current Progress and Challenges , 2021, Nanoscale Research Letters.
[24] R. Ullah,et al. Mild Hyperthermia Responsive Liposomes for Enhanced In Vitro and In Vivo Anticancer Efficacy of Doxorubicin against Hepatocellular Carcinoma , 2021, Pharmaceutics.
[25] K. Evason,et al. Exploring the Interplay of Telomerase Reverse Transcriptase and β-Catenin in Hepatocellular Carcinoma , 2021, Cancers.
[26] V. Torchilin,et al. Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment , 2021, Journal of personalized medicine.
[27] Xiangxian Ying,et al. Antitumor Activity and Potential Mechanism of Novel Fullerene Derivative Nanoparticles , 2021, Molecules.
[28] J. Calderaro,et al. Pathologic and molecular features of hepatocellular carcinoma: An update , 2021, World journal of hepatology.
[29] P. Galle,et al. The Current Landscape of Clinical Trials for Systemic Treatment of HCC , 2021, Cancers.
[30] S. Beg,et al. Nanotechnology Based Approach for Hepatocellular Carcinoma Targeting. , 2020, Current Drug Targets.
[31] Nicholas A. Peppas,et al. Engineering precision nanoparticles for drug delivery , 2020, Nature reviews. Drug discovery.
[32] Y. Chang,et al. Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma , 2020, International journal of molecular sciences.
[33] Ju Dong Yang,et al. New advances in the diagnosis and management of hepatocellular carcinoma , 2020, BMJ.
[34] Yihan Yao,et al. Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance , 2020, Frontiers in Molecular Biosciences.
[35] Hang Zhao,et al. Multifunctional Gold Nanoparticles: A Novel Nanomaterial for Various Medical Applications and Biological Activities , 2020, Frontiers in Bioengineering and Biotechnology.
[36] A. Lechel,et al. Telomeres and Telomerase in the Development of Liver Cancer , 2020, Cancers.
[37] E. D. De Toni,et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects , 2020, Signal Transduction and Targeted Therapy.
[38] G. Nagaraju,et al. Nanotheranostics: Their role in hepatocellular carcinoma. , 2020, Critical reviews in oncology/hematology.
[39] M. C. Bonferoni,et al. Chitosan Nanoparticles for Therapy and Theranostics of Hepatocellular Carcinoma (HCC) and Liver-Targeting , 2020, Nanomaterials.
[40] C. Jasirwan,et al. The alpha-fetoprotein serum is still reliable as a biomarker for the surveillance of hepatocellular carcinoma in Indonesia , 2020, BMC Gastroenterology.
[41] Carol S. Lim,et al. Advances in delivery vectors for gene therapy in liver cancer. , 2019, Therapeutic delivery.
[42] C. Moonen,et al. Tumor Drug Distribution after Local Drug Delivery by Hyperthermia, In Vivo , 2019, Cancers.
[43] Pedro Pedrosa,et al. Nanotheranostics Targeting the Tumor Microenvironment , 2019, Front. Bioeng. Biotechnol..
[44] Y. Greish,et al. Current status of nanomaterial-based treatment for hepatocellular carcinoma. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[45] P. Bose,et al. Advances in early diagnosis of hepatocellular carcinoma , 2019, Hepatoma Research.
[46] M. Heikenwalder,et al. From NASH to HCC: current concepts and future challenges , 2019, Nature Reviews Gastroenterology & Hepatology.
[47] R. Duran,et al. Theranostics in Interventional Oncology: Versatile Carriers for Diagnosis and Targeted Image-Guided Minimally Invasive Procedures , 2019, Front. Pharmacol..
[48] Jingwen Peng,et al. Progress in research on gold nanoparticles in cancer management , 2019, Medicine.
[49] P. Sil,et al. Role of nanostructures in improvising oral medicine , 2019, Toxicology reports.
[50] Dong-Jin Lim,et al. Gold Nanoparticles for Photothermal Cancer Therapy , 2019, Front. Chem..
[51] J. Prados,et al. Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment , 2019, Nanomaterials.
[52] Y. Ghasemi,et al. Gold nanoparticles application in liver cancer. , 2019, Photodiagnosis and photodynamic therapy.
[53] T. de Baère,et al. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. , 2019, Cancer treatment reviews.
[54] M. Bally,et al. Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response , 2018, International journal of molecular sciences.
[55] Leonardo Fernandes Fraceto,et al. Nano based drug delivery systems: recent developments and future prospects , 2018, Journal of Nanobiotechnology.
[56] Kyoungju Choi,et al. Assessment of Gold Nanoparticles-Inhibited Cytochrome P450 3A4 Activity and Molecular Mechanisms Underlying Its Cellular Toxicity in Human Hepatocellular Carcinoma Cell Line C3A , 2018, Nanoscale Research Letters.
[57] Priyanka Singh,et al. Gold Nanoparticles in Diagnostics and Therapeutics for Human Cancer , 2018, International journal of molecular sciences.
[58] J. Karlsson,et al. Biodegradable Polymeric Nanoparticles for Therapeutic Cancer Treatments. , 2018, Annual review of chemical and biomolecular engineering.
[59] J. Marrero,et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. , 2018, Gastroenterology.
[60] James R. Smith,et al. Liposomal Drug Delivery Systems and Anticancer Drugs , 2018, Molecules.
[61] Wei Hu,et al. Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy , 2018, International journal of nanomedicine.
[62] Satya Gupta,et al. Recent advances in carbon nanotube based electrochemical biosensors. , 2018, International journal of biological macromolecules.
[63] A. Singal,et al. Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review , 2017, Journal of clinical and translational hepatology.
[64] A. Goyal,et al. Recent advances in metal nanoparticles in cancer therapy , 2017, Journal of drug targeting.
[65] Xu Li,et al. Diabetes Mellitus and Risk of Hepatocellular Carcinoma , 2017, BioMed research international.
[66] K. Sandeep,et al. Liposomes for Drug Delivery , 2017 .
[67] Alan D. Lopez,et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level , 2017, JAMA oncology.
[68] P. Couzigou,et al. Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma , 2017, ESMO Open.
[69] Kristofer J. Thurecht,et al. Bridging Bio-Nano Science and Cancer Nanomedicine. , 2017, ACS nano.
[70] Qiang Shen,et al. Cancer drug delivery in the nano era: An overview and perspectives , 2017, Oncology reports.
[71] Jie Tan,et al. An ‘activatable’ aptamer-based fluorescence probe for the detection of HepG2 cells , 2017, Oncology reports.
[72] K. Hynynen,et al. To heat or not to heat: Challenges with clinical translation of thermosensitive liposomes , 2017, Journal of controlled release : official journal of the Controlled Release Society.
[73] Shiming Yang,et al. Current applications and future prospects of nanomaterials in tumor therapy , 2017, International journal of nanomedicine.
[74] A. R. Fernandes,et al. Gold Nanoparticle Approach to the Selective Delivery of Gene Silencing in Cancer—The Case for Combined Delivery? , 2017, Genes.
[75] A. Yari Khosroushahi,et al. Overviews on the cellular uptake mechanism of polysaccharide colloidal nanoparticles , 2017, Journal of cellular and molecular medicine.
[76] Rong Zheng,et al. Aptamer Combined with Fluorescent Silica Nanoparticles for Detection of Hepatoma Cells , 2017, Nanoscale Research Letters.
[77] G. Jiang,et al. Application of Nanotechnology in the Diagnosis and Therapy of Hepatocellular Carcinoma. , 2016, Recent patents on anti-cancer drug discovery.
[78] R. Lencioni,et al. RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma. , 2016, Hepatic oncology.
[79] N. Fidelman,et al. Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: Where do we stand with tumor down‐staging? , 2016, Hepatology.
[80] H. H. Oh,et al. Multiple Bone Metastases as the First Manifestation of Hepatocellular Carcinoma in Patient with Noncirrhotic Liver , 2015, Case reports in oncological medicine.
[81] Wei Guo,et al. Screening and Identifying a Novel ssDNA Aptamer against Alpha-fetoprotein Using CE-SELEX , 2015, Scientific Reports.
[82] D. Haemmerich,et al. Increased Duration of Heating Boosts Local Drug Deposition during Radiofrequency Ablation in Combination with Thermally Sensitive Liposomes (ThermoDox) in a Porcine Model , 2015, PloS one.
[83] Y. Rolland,et al. Clinical impact of 99mTc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with 90Y-loaded microspheres , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[84] M. Owais,et al. Nano-Sized Drug Delivery Systems: Development and Implication in Treatment of Hepatocellular Carcinoma , 2015, Digestive Diseases.
[85] Hiroshi Maeda,et al. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. , 2015, Advanced drug delivery reviews.
[86] Min-yan Wei,et al. Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma , 2015, International journal of nanomedicine.
[87] A. Kouzani,et al. Superior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid Tumors , 2015, Theranostics.
[88] B. Ghosh,et al. Current trends in using polymer coated gold nanoparticles for cancer therapy. , 2015, International journal of pharmaceutics.
[89] K. Simon,et al. Diagnostic Challenges in Primary Hepatocellular Carcinoma: Case Reports and Review of the Literature , 2015, Case reports in oncological medicine.
[90] Ji-Ho Park,et al. Endocytosis and exocytosis of nanoparticles in mammalian cells , 2014, International journal of nanomedicine.
[91] A. Raza,et al. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. , 2014, World journal of gastroenterology.
[92] Yoshito Itoh,et al. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. , 2014, World journal of gastroenterology.
[93] B. Guiu,et al. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. , 2013, Critical reviews in oncology/hematology.
[94] A. K. Kondapi,et al. A Target-Specific Oral Formulation of Doxorubicin-Protein Nanoparticles: Efficacy and Safety in Hepatocellular Cancer , 2013, Journal of Cancer.
[95] Zhen Zhang,et al. Aflatoxin B1-induced hepatocellular carcinoma in developing countries: Geographical distribution, mechanism of action and prevention , 2013, Oncology letters.
[96] Qing He,et al. Transcatheter Arterial Chemoembolization: History for More than 30 Years , 2012, ISRN gastroenterology.
[97] Gang Liu,et al. High-sensitivity nanosensors for biomarker detection. , 2012, Chemical Society reviews.
[98] N. Desai. Challenges in Development of Nanoparticle-Based Therapeutics , 2012, The AAPS Journal.
[99] Seong-Wook Lee,et al. Regression of hepatocarcinoma cells using RNA aptamer specific to alpha-fetoprotein. , 2012, Biochemical and biophysical research communications.
[100] J. Bruix,et al. Management of HCC. , 2012, Journal of hepatology.
[101] M. Prasanth,et al. Interventional Radiological Treatment of Hepatocellular Carcinoma: An Update , 2012, Indian Journal of Surgery.
[102] T. Murakami,et al. Ultrasonography, Computed Tomography and Magnetic Resonance Imaging of Hepatocellular Carcinoma: Toward Improved Treatment Decisions , 2011, Oncology.
[103] M. Thanou,et al. Targeting nanoparticles to cancer. , 2010, Pharmacological research.
[104] Priyabrata Mukherjee,et al. Gold nanoparticles: opportunities and challenges in nanomedicine , 2010, Expert opinion on drug delivery.
[105] J. Geschwind,et al. Intra-Arterial Therapies for Hepatocellular Carcinoma: Where Do We Stand? , 2010, Annals of Surgical Oncology.
[106] R. Barrangou,et al. CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes , 2007, Science.
[107] J. D. Elliott,et al. New Strategies in Drug Discovery , 2006, Methods in molecular biology.
[108] R. Jain. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.
[109] T. Morgan,et al. Alcohol and hepatocellular carcinoma. , 2004, Gastroenterology.
[110] L. Pączek,et al. [Liver transplantation for hepatocellular carcinoma]. , 2003, Polskie Archiwum Medycyny Wewnetrznej.
[111] J. Bruix,et al. Hepatitis B virus and hepatocellular carcinoma. , 2003, Journal of hepatology.
[112] M. Al-Ahwal,et al. Chemoembolization in hepatocellular carcinoma. , 1998, Saudi medical journal.
[113] M. Colombo,et al. Epidemiology of hepatocellular carcinoma. , 1995, The Italian journal of gastroenterology.
[114] G. Kruh,et al. Doxorubicin and multidrug resistance , 1993, Current opinion in oncology.
[115] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.